CTRI/2022/09/046081进行中（未招募）未知
SAFETY AND EFFICACY OF SAROGLITAZAR IN PATIENTS WITH NON-OBESE NAFLD: OPEN LABEL RANDOMISED CONTROL TRIA
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with normal BMI ( >18 to < 25 kg/m2) diagnosed as NAFLD defined by the presence of hepatic steatosis on ultrasound or using CAP parameters (of FibroScan) in absence significant consumption of alcohol ( <20g/day) irrespective of gender after ruling out other etiologies of other etiologies for hepatic steatosis or elevated transaminases including but not limited to chronic viral hepatitis, autoimmune Hepatitis, hemochromatosis, Wilson disease, celiac disease, drug induced liver injury (DILI), etc. and having LSM <13.6 kPa
排除标准
- •Patients with BMI >= 25 kg/m2, age <18 years or >75 years of age.
- •Patients with cirrhosis or with HCC or any other malignancy.
- •Patients with concomitant other etiologies for hepatic steatosis or elevated transaminases. Patients already on Vitamin E or pioglitazone.
- •Pregnant or lactating.
- •Patients too sick or not consenting to participate in the study
研究者
相似试验
尚未招募
不适用
To find out effect and safety of drug saroglitazar alone and in combination with vitamin E in patients having non alcoholic fatty deposition in liverCTRI/2021/07/034946Pt BD Sharma PGIMS Rohtak
已完成
不适用
Drug trial between new drug Saroglitazar with existing drug Fenofibrate in patients with diabetesCTRI/2019/02/017410Maulana azad medical college
尚未招募
Unknown
Effect of saroglitazar in patients with diabetes mellitusCTRI/2023/09/057322JIPMER Intramural fund
进行中（未招募）
不适用
Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study.Diabetic peripheral neuropathic painMedDRA version: 12.0Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painEUCTR2009-015066-61-ATSanofi-Aventis Recherche & Développement80
进行中（未招募）
不适用
Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study.Diabetic peripheral neuropathic painMedDRA version: 12.0Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painEUCTR2009-015066-61-DESanofi-Aventis Recherche & Développement80